Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-04-30T16:05:19.170Z Has data issue: false hasContentIssue false
  • English
  • Français

The impact of the American Heart Association guidelines on patients treated for incomplete Kawasaki disease

Part of: Infectious

Published online by Cambridge University Press:  06 September 2021

Megan M. Blaney Open the ORCID record for Megan M. Blaney [Opens in a new window] ,
Richard V. Williams ,
Igor A. Areinamo ,
Michael Sauer ,
Lloyd Y. Tani ,
Zhining Ou ,
L. LuAnn Minich  and
Dongngan T. Truong Open the ORCID record for Dongngan T. Truong [Opens in a new window]
Megan M. Blaney*
Affiliation:
Division of Pediatrics, University of Utah, Salt Lake City, UT, USA
Richard V. Williams
Affiliation:
Division of Pediatric Cardiology, University of Utah, Salt Lake City, UT, USA
Igor A. Areinamo
Affiliation:
Division of Pediatrics, Children’s Mercy Kansas City, Kansas City, MO, USA
Michael Sauer
Affiliation:
Division of Pediatrics, University of Utah, Salt Lake City, UT, USA
Lloyd Y. Tani
Affiliation:
Division of Pediatric Cardiology, University of Utah, Salt Lake City, UT, USA
Zhining Ou
Affiliation:
Division of Pediatric Cardiology, University of Utah, Salt Lake City, UT, USA
L. LuAnn Minich
Affiliation:
Division of Pediatric Cardiology, University of Utah, Salt Lake City, UT, USA
Dongngan T. Truong
Affiliation:
Division of Pediatric Cardiology, University of Utah, Salt Lake City, UT, USA
*
Author for correspondence: M.M. Blaney, MD, Division of Pediatric Cardiology, University of Utah, 81 N. Mario Capecchi Drive, Salt Lake City, UT 84113, USA. Tel: 801 662 1000. E-mail: megan.blaney@hsc.utah.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives:

To compare patients treated for incomplete Kawasaki disease whose practitioners followed versus did not follow American Heart Association criteria and to evaluate the association of cardiology consultation with adherence to these guidelines.

Study design:

Single centre retrospective cohort study of patients <18 years old who received ≥1 dose of intravenous immunoglobulin for Kawasaki disease between 01/2006 and 01/2018. We collected demographics, clinical and laboratory data, coronary artery abnormalities, and cardiology consultation status. Patients treated for incomplete Kawasaki disease were divided into two groups based on adherence versus nonadherence to American Heart Association guidelines and compared by Wilcoxon rank sum test and chi-squared or Fisher’s exact test.

Results:

Of the 357 patients treated for Kawasaki disease, 109 (31%) were classified as incomplete Kawasaki disease. The American Heart Association algorithm for identifying patients with incomplete Kawasaki disease was followed in 81/109 (74%). Coronary artery abnormalities were present in 46/109 (42%) of the patients who were treated for incomplete Kawasaki disease. Cardiology consultation was more frequent in those fulfilling American Heart Association criteria for the diagnosis of incomplete Kawasaki disease versus those who did not fulfill criteria (76% versus 48%, p = 0.005).

Conclusions:

Over 25% of patients treated for incomplete Kawasaki disease did not meet American Heart Association guidelines. Guidelines were more frequently followed when the paediatric cardiology team was consulted. Consulting physicians with experience and expertise in the evaluation and management of incomplete KD should be strongly considered in the care of these patients.

Keywords

Kawasaki diseaseincomplete Kawasaki diseaseAmerican Heart Association guidelinescardiology consultation
Type
Original Article
Information
Cardiology in the Young , Volume 32 , Issue 7 , July 2022 , pp. 1066 - 1070
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Newburger, JW, Takahashi, M, Gerber, MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. Circulation 2004; 110: 2747–2771. DOI 10.1161/01.CIR.0000145143.19711.78.CrossRefGoogle ScholarPubMed
McCrindle, BW, Rowley, AH, Newburger, JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. Circulation 2017; 135: e927–e999. DOI 10.1161/CIR.0000000000000484.CrossRefGoogle ScholarPubMed
Witt, MT, Minich, LL, Bohnsack, JF, Young, PC. Kawasaki disease: more patients are being diagnosed who do not meet American Heart Association criteria. Pediatrics 1999; 104: e10–e10. DOI 10.1542/peds.104.1.e10.CrossRefGoogle Scholar
Sonobe, T, Kiyosawa, N, Tsuchiya, K, et al. Prevalence of coronary artery abnormality in incomplete Kawasaki disease. Pediatr Int 2007; 49: 421–426. DOI 10.1111/j.1442-200X.2007.02396.x.CrossRefGoogle ScholarPubMed
Sudo, D, Monobe, Y, Yashiro, M, et al. Coronary artery lesions of incomplete Kawasaki disease: a nationwide survey in Japan. Eur J Pediatr 2012; 171: 651–656. DOI 10.1007/s00431-011-1630-3.CrossRefGoogle ScholarPubMed
Yellen, ES, Gauvreau, K, Takahashi, M, et al. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics 2010; 125: e234–41. DOI 10.1542/peds.2009-0606.CrossRefGoogle ScholarPubMed
Grignani, R, Quek, S. Kawasaki disease in 2019-past controversies, present insights and future directions. Pediatr Medicine 2019; 2: 10. DOI 10.21037/pm.2019.03.03.10.21037/pm.2019.03.03CrossRefGoogle Scholar
Guo, Y, Tian, X, Wang, X, et al. Adverse effects of immunoglobulin therapy. Front Immunolo 2018; 9: 1299. DOI 10.3389/fimmu.2018.01299.CrossRefGoogle ScholarPubMed